Summary: Biologic therapies are transforming the treatment of disease and improving the lives of millions. We have the passion to help you accelerate, simplify and de-risk...

Summary: GPEx® Boost is the next generation of cell line development, designed to improve productivity by leveraging proven GPEx® technology with multiple enhancements, including utilization of a glutamine synthetase...

Summary: OneBio™ Suite provides integrated biologics development, manufacturing and supply with a single solution from cell line development through clinical supply. OneBio Suite is designed...

Summary: The propensity of a protein to degrade under stress can vary widely among proteins and is important to understand in pharmaceutical development. A model protein, adalimumab, was tested by a limited...

Summary: This poster evaluates the degradation of a therapeutic mAb, Adalimumab, resulting from light, shear and thermal stress.  Degradation was evaluated using a combination of Sedimentation...

Summary: While everyone wants a Breakthrough Therapy Designation (BTD), Fast Track or PRIME, these designations also add to the pressure of getting a drug to the clinic under tight timelines....

Summary: Pharma companies are always examining ways to increase efficiencies and reduce cost of drug development. While cost of goods sold (COGS) can be...

Summary: In this webinar, Charlotte Lukas from AstraZeneca and Amanda Henry, project management expert discussed a case study on a 30-day commercial launch plan for a product into new markets and why this approach was important for patients.

Summary: Achieve higher titers by leveraging the power of proven GPEx® Technology with a glutamine synthetase knockout CHO cell line.

Summary: Typically, in early development, the quantity of protein available for studies is limited, and a dataset is required to expedite Tox- and IND-enabling stability studies. In this study, a high-throughput formulation development...